Enterprise Value

1.442B

Cash

254.9M

Avg Qtr Burn

N/A

Short % of Float

10.11%

Insider Ownership

5.12%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Qelbree (viloxazine hydrochloride) Details
Mental health, Attention deficit hyperactivity disorder

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Gocovri (Amantadine) Details
Parkinson's disease for OFF episodes

Approved

Quarterly sales

Trokendi XR® (topiramate) Details
Prophylaxis of migraine

Approved

Quarterly sales

Gocovri (Amantadine) Details
Dyskinesia (Parkinson's disease)

Approved

Quarterly sales

Namzaric Details
Alzheimer's Dementia

Approved

Quarterly sales

Osmolex ER (amantadine) Details
PD (Parkinson's Disease)

Approved

Quarterly sales

MYOBLOC® (rimabotulinumtoxinB) Details
Cervical Dystonia Sialorrhea

Approved

Quarterly sales

XADAGO (safinamide) Details
Parkinson's disease

Approved

Quarterly sales

SPN-830 (apomorphine infusion device) Details
Parkinson's disease, Brain disease

NDA

Resubmission

SPN-820/821 Details
Mental health, Treatment Resistant Depression, Major depressive disorder

Phase 2b

Data readout

Phase 2a

Data readout